Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis

Hepatology Research

Volumn 37, Issue SUPPL. 3, 2007, Pages

  Nakamura, Minoru ^a,b,c   Komori, Atsumasa ^a,b   Ito, Masahiro ^a,b   Kondo, Hisayoshi ^b   Aiba, Yoshihiro ^a   Migita, Kiyoshi ^a,b   Nagaoka, Shinya ^a   Ohata, Kazuyuki ^a   Yano, Koji ^a   Abiru, Seigo ^a   Daikoku, Manabu ^a   Yatsuhashi, Hiroshi ^a,b   Shimoda, Shinji ^d   Ishibashi, Hiromi ^a,c  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c National Hospital Organization   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Antinuclear antibodies (ANA); Centromere; Gp210; Hepatic failure; Predictive autoantibodies; Primary biliary cirrhosis (PBC)

Indexed keywords

ANTIBODY; ANTIGEN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BRANCHED CHAIN 2 OXOACID DEHYDROGENASE COMPLEX; BRANCHED CHAIN 2 OXOACID DEHYDROGENASE COMPLEX E2; CELL NUCLEUS ANTIGEN; CENTROMERE ANTIBODY; CENTROMERE PROTEIN B; GLYCOPROTEIN GP210 ANTIBODY; LAMIN B RECEPTOR; MITOCHONDRION ANTIBODY; OXAGLUTARATE DEHYDROGENASE COMPLEX; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P62; PROTEIN SP100; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATE DEHYDROGENASE COMPLEX E1A; PYRUVATE DEHYDROGENASE COMPLEX E2; PYRUVATE DEHYDROGENASE COMPLEX E3BP; SUMO PROTEIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

AGE; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN EXPRESSION; CAUSE OF DEATH; CONFERENCE PAPER; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MOLECULAR MIMICRY; MOLECULAR RECOGNITION; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; RISK FACTOR; SEX DIFFERENCE; T LYMPHOCYTE;

EID: 35348899452     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00244.x     Document Type: Conference Paper

References (17)

1. Rubin E, Schaffner F, Popper H. Primary biliary cirrhosis. Am J Pathol 1965; 46: 387-407.
2. Ishibashi H, Shimoda S, Gershwin ME. The immune response to mitochondrial antigens. Semin Liver Dis 2005; 25: 337-46.
3. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 79-90.
4. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25: 298-310.
5. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA DRB4 0101-restricted immunodominant T-cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: Evidence of molecular mimicry in human autoimmune diseases. J Exp Med 1995; 181: 1835-45.
6. Shigematsu H, Shimoda S, Nakamura M et al. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: Implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology 2000; 32: 901-9.
7. Shimoda S, Nakamura M, Shigematsu H et al. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T cell epitope of primary biliary cirrhosis. Hepatology 2000; 31: 1212-16.
8. Shimoda S, Nakamura M, Ishibashi H et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 2003; 124: 1915-25.
9. Itoh S, Ichida T, Yoshida T et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998; 13: 257-65.
10. Invernizzi P, Podda M, Battezzati PM et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001; 34: 366-72.
11. Muratori P, Muratori L, Ferrari R et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 431-7.
12. Miyachi K, Hankins RW, Matsushima H et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: A multicenter study. J Autoimmun 2003; 20: 247-54.
13. Yang W-H, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure. Clin Gastroenterol Hepatol 2004; 2: 1116-22.
14. Nakamura M, Shimizu-Yoshida Y, Takii Y et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005; 42: 386-92.
15. Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.
16. Nakamura M, Takii Y, Ito M et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J Autoimmun 2006; 26: 138-45.
17. Wesierska-Gadek J, Penner E, Battezzati PM et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43: 1135-44.